Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169,629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
Xu B, Pan Q, Pan H, Li H, Li X, Chen J, Pang D, Zhang B, Weng D, Peng R, Fang M, Zhang X. Xu B, et al. Among authors: zhang b, zhang x. EClinicalMedicine. 2023 Sep 21;64:102240. doi: 10.1016/j.eclinm.2023.102240. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37767191 Free PMC article.
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study.
Huang Z, Yan H, Zeng L, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Dong X, Yang N, Zhang Y. Huang Z, et al. Among authors: zhang l, zhang r, zhang x, zhang y. JCO Precis Oncol. 2023 Mar;7:e2200614. doi: 10.1200/PO.22.00614. JCO Precis Oncol. 2023. PMID: 36952645
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
Zeng L, Song L, Liu L, Wu F, Xu Q, Yan H, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Xiao J, Liu M, Liu Z, Zhang L, Zhou C, Xiong Y, Wang Y, Zhang Y, Yang N. Zeng L, et al. Among authors: zhang l, zhang x, zhang y. Med. 2024 May 10;5(5):445-458.e3. doi: 10.1016/j.medj.2024.02.011. Epub 2024 Mar 22. Med. 2024. PMID: 38521070 Clinical Trial.
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H, Song L, Li Y, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Huang Z, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zhang Y, Zeng L. Yan H, et al. Among authors: zhang l, zhang r, zhang g, zhang x, zhang y. Cancer Immunol Immunother. 2024 Mar 7;73(4):74. doi: 10.1007/s00262-024-03660-2. Cancer Immunol Immunother. 2024. PMID: 38451314 Free PMC article.
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Huang Z, Zhang Y, Xu Q, Song L, Li Y, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zeng L, Zhang Y. Huang Z, et al. Among authors: zhang l, zhang r, zhang g, zhang x, zhang y. Lung Cancer. 2024 May 21;192:107827. doi: 10.1016/j.lungcan.2024.107827. Online ahead of print. Lung Cancer. 2024. PMID: 38795459
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Zhang P, Chen Z, Shi S, Li Z, Ye F, Song L, Zhang Y, Yin F, Zhang X, Xu J, Cheng Y, Su W, Shi M, Fan S, Tan P, Zhong C, Lu M, Shen L. Zhang P, et al. Among authors: zhang x, zhang y. Cancer Immunol Immunother. 2024 May 7;73(7):119. doi: 10.1007/s00262-024-03677-7. Cancer Immunol Immunother. 2024. PMID: 38713205 Free PMC article. Clinical Trial.
169,629 results
You have reached the last available page of results. Please see the User Guide for more information.